FreeBioList

Catalysts / AVIR

Atea Pharmaceuticals (AVIR) catalysts

Upcoming FDA decisions and readouts we track for Atea Pharmaceuticals, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 2 Rows last checked — 12 Sep 2026

FreeBioList tracks 2 upcoming catalysts for Atea Pharmaceuticals (AVIR, listed on Nasdaq). Both concern Bemnifosbuvir + ruzasvir (Chronic hepatitis C).

First on the list: the Phase 3 readout for Bemnifosbuvir + ruzasvir (Chronic hepatitis C), guided by the company to Q1 2027. By stage, the upcoming rows are 1 Phase 3 readout and 1 Regulatory submission.

Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: How to read a Phase 3 topline readout; NDA vs BLA: the two kinds of US drug application.

Ticker
AVIR
Next catalyst
Q1 2027
Type
Phase 3 readout
Listed options
Yes
Company ▾ Drug ▾ Effect / indication Next catalyst ▾ Phase / type ▾ Status ▾ Source Options
Atea Pharmaceuticals AVIR · Nasdaq Bemnifosbuvir + ruzasvir Chronic hepatitis C Q1 2027
company guidance		 Phase 3 readout Verified 8-K exhibit 99.1 ↗ Yes
Atea Pharmaceuticals AVIR · Nasdaq Bemnifosbuvir + ruzasvir Chronic hepatitis C Q2 2027
company guidance		 Regulatory submission Verified 8-K exhibit 99.1 ↗ Yes

Companies working on related conditions

Also due in Q1 2027